Sudan ebolavirus vaccine

The Sudan ebolavirus vaccine refers to several investigational vaccines developed to prevent infection by the Sudan ebolavirus (SUDV), a species of Ebolavirus responsible for severe hemorrhagic fever outbreaks with high fatality rates. There are currently no approved vaccines for SUDV. Multiple candidates are in clinical development: - **rVSV-SUDV** is a recombinant vesicular stomatitis virus-based vaccine engineered to express the glycoprotein of the Sudan virus. This triggers an immune response that generates protective antibodies against SUDV. Developed by IAVI, it has shown safety and immunogenicity in Phase 1 trials and is being tested for efficacy in Uganda[1][3][8]. - **cAd3-SUDV** is based on a chimpanzee adenovirus serotype 3 vector platform (the same as Sabin’s Marburg candidate). It is designed as a single-dose regimen and has demonstrated rapid and robust immune responses lasting up to 12 months in early studies[4]. - **SuVax** is a subunit protein vaccine composed of recombinantly expressed SUDV glycoprotein with a novel nano-emulsion adjuvant, developed by Soligenix. It has received FDA Orphan Drug designation after showing complete protection in nonhuman primate models and thermostability at high temperatures[5]. Primary indication for all these candidates is prevention of disease caused by the Sudan ebolavirus.

Brand names

SuVax

Other names

Sudan Ebola virus vaccineSUDV vaccine